Exvade Bioscience

Exvade Bioscience is a biotechnology company focused on developing next-generation oncolytic virus therapies designed for systemic administration. The company's core technology addresses the limitation of current viral therapies, which are often neutralized by the immune system before reaching metastatic sites. By leveraging extracellular vesicles (exosomes) to encapsulate and shield viruses, Exvade enables intravenous delivery, potentially allowing for the treatment of widespread cancer rather than just localized tumors. This "stealth" approach protects the viral payload from neutralizing antibodies during circulation, enhancing the therapeutic window. The company's platform aims to expand the reach of viral immunotherapy to include metastatic disease, which remains a significant challenge in oncology. Exvade is currently advancing its lead programs through pre-clinical development to establish a new standard for viral-based cancer treatment.